Youtor
Osteoarthritis vs Rheumatoid Arthritis Causes amp Remedies Dr Alan Mandell DC
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=r23viUKVQVQ
📌 𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐧 𝐈𝐧𝐬𝐭𝐚𝐠𝐫𝐚𝐦:- / drgbhanuprakash • 📌𝗝𝗼𝗶𝗻 𝗢𝘂𝗿 𝗧𝗲𝗹𝗲𝗴𝗿𝗮𝗺 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗛𝗲𝗿𝗲:- https://t.me/bhanuprakashdr • 📌𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗧𝗼 𝗠𝘆 𝗠𝗮𝗶𝗹𝗶𝗻𝗴 𝗟𝗶𝘀𝘁:- https://linktr.ee/DrGBhanuprakash • Classification of Anti Rheumatoid Drugs - Pharmacology • Rheumatoid arthritis (RA) is an inflammatory autoimmune disorder characterized by joint pain, swelling, and synovial destruction. RA predominantly affects middle-aged women. The condition can also cause various extra-articular manifestations such as rheumatoid nodules and pulmonary fibrosis. Diagnosis is mainly based on clinical features (e.g., morning stiffness, symmetrical joint swelling) and laboratory tests (e.g., anti-CCP). X-ray findings (e.g., soft tissue swelling or joint space narrowing) occur late in the disease and are therefore not typically used for diagnosis. Early intervention with disease-modifying antirheumatic drugs (DMARDs) plays a decisive role in successful treatment. RA is not curable, but early effective treatment may help offset severe complications (e.g., permanent damage to the affected joints). • General measures • ----------------------------- • For acute episodes of inflammation: cryotherapy • Physical and occupational therapy • Physical activity • Acute anti-inflammatory therapy • ---------------------------------------------------- • Indication: acute attack • Glucocorticoids: given until DMARD's onset of action or as long-term therapy for highly active RA. • Systemic • Intra-articular injections of PRN • Prevention of osteoporosis: optimization of sufficient calcium and vitamin D intake • NSAIDs and COX-2 inhibitors: symptomatic relief without improving prognosis • PPIs are recommended because combining glucocorticoids with NSAIDs substantially increases the risk of GI ulcers. • Long-term anti-inflammatory therapy with disease-modifying antirheumatic drugs (DMARDs) • ---------------------------------------------------------------------------------------------------------------------------------------------------- • Induce immunosuppression, leading to potential remission of RA • Reduce mortality and morbidity by up to 30% • Slow progression of disease • Preserve joint function • Limit complications • Slow onset of action (≥ 6 weeks), so symptomatic treatment with glucocorticoids and NSAIDs is often required • Non-biologic agents • --------------------------------- • Drug of choice: methotrexate (MTX) • First-line treatment for moderate to severe RA • Benefits: highly effective, relatively well-tolerated, low cost, possibly life-prolonging • Gastrointestinal side effects , rash, hepatotoxicity (abnormal liver chemistry), interstitial pneumonitis and pulmonary fibrosis, bone marrow suppression , nephrotoxicity, increased risk of lymphoproliferative disorders, teratogenicity, alopecia • To minimize side effects, folic acid is recommended 24–48 hours after taking MTX. • Do not give NSAIDs on the same day as MTX, as they can worsen the side effects of MTX by inhibiting its renal excretion . • Alternative drugs: • Leflunomide • Hydroxychloroquine • Sulfasalazine: for use in pregnancy • Biologic therapy • -------------------------- • Indication: moderate or severe disease activity remaining after three months of DMARD therapy • Should be combined with non-biologic DMARDs • Tumor necrosis factor (TNF) α inhibitors: e.g., adalimumab, infliximab, etanercept • See contraindications to anti-TNF-α treatment. • Others: rituximab (anti-CD20) and anakinra (interleukin-1 receptor antagonist, particularly for Still disease) • Early administration of DMARDs is crucial for a better outcome! • #ClassificationofAntiRheumatoidDrugs #AntiRheumatoidDrugs #pharmacology #usmle #neetpg #mbbs #fmge
#############################
